Thu, Dec 25, 2014, 11:03 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

  • kristerlag kristerlag Dec 9, 2010 4:31 PM Flag

    THE NEWS 12-09-2010

    Hi!

    This is todays news in sweden!
    Translated by google!
    http://translate.google.com

    Swe to Eng!

    EpiCept: Rodman & Renshaw REBELLION price target 2 USD E ASH CONFERENCE (Direct)
    2010-12-09 09:59

    (Bloomberg) Rodman & Renshaw reiterates outperform recommendation on EpiCept after the company unveiled a study at the ASH conference. The target price is $ 2, corresponding to 13:72 crowns, implying a significant upside to Wednesday's closing price of SEK 3:09.

    According to a sector analysis dated December 8.

    EpiCept presented results from a meta-analysis of Ceplene with interleukin-2 (IL-2), a study that was part of the company's filing for Ceplene. Using two statistical models, researchers have found that Ceplene and IL-2 has an advantage over the standard treatment and IL-2.

    "It should be noted that this conclusion is robust with respect to modeling assumptions," said Rodman & Renshaw.

    Rodman & Renshaw concluded that the observed leukemia-free survival of Ceplene and IL-2 over IL-2 and standard treatment is clinically relevant and should generate interest in immunotherapy as a means of maintaining the regression and prevent relapse in AML patients.

    Jonas Aronsson +46 8 5191 7914
    Direkt
    https://www.avanza.se/aza/press/news.jsp?newsArticleId=1715358

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • EpiCept rocket rushes
      Published: 2010-12-09 13:33
      EpiCept Exchange is acidic, but the biotechnology company EpiCept shares go against the tide on Thursday. The share has risen during the day by nearly 80 percent.
      The reason that EpiCept rush is seemingly recommendation from Rodman & Renshaw, who reiterates outperform on EpiCept. This after the company unveiled a study at the ASH conference. The target price is $ 2, corresponding to 13:72 crowns, implying a significant upside to Wednesday's closing price of SEK 3:09.

      According to a sector analysis dated December 8.

      EpiCept presented results from a meta-analysis of Ceplene with interleukin-2 (IL-2), a study that was part of the company's filing for Ceplene. Using two statistical models, researchers have found that Ceplene and IL-2 has an advantage over the standard treatment and IL-2.

      "It should be noted that this conclusion is robust with respect to modeling assumptions," said Rodman & Renshaw.

      Rodman & Renshaw concluded that the observed leukemia-free survival of Ceplene and IL-2 over IL-2 and standard treatment is clinically relevant and should generate interest in immunotherapy as a means of maintaining the regression and prevent relapse in AML patients.


      Direkt
      redaktionen@placera.nu
      More of News Agency Direkt

      https://www.avanza.se/aza/press/press_article.jsp?article=182223&mbFromPage=Ă–versiktssida

 
IMNP
1.89+0.02(+1.07%)Dec 24 12:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.